Search Results for keywords:"HIV"

The Centers for Disease Control and Prevention (CDC) is inviting public comment on a proposed study, as per the Paperwork Reduction Act of 1995, aimed at improving HIV diagnosis and care services using Point-of-Care Nucleic Acid Tests (NATs). This study, known as the Greater Access and Impact with NAT (GAIN) Study, seeks to identify challenges and supportive factors in implementing these tests in clinical settings and assess their effectiveness in speeding up HIV prevention and care. Public comments are invited until March 10, 2025, and the CDC is asking for insights on the necessity, accuracy, and cost-effectiveness of the data collection process associated with this study.

The Centers for Disease Control and Prevention (CDC) is reorganizing its National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) to better address public health challenges related to these diseases. Changes include updating the mission statement and restructuring various offices and branches within the center to improve coordination, research, and prevention efforts. The reorganization aims to enhance the effectiveness of programs, improve collaboration with partners, and focus on health equity and reducing health disparities. This initiative reflects CDC's commitment to using the best scientific data to guide public health decisions.

The Centers for Disease Control and Prevention (CDC) has submitted a proposal for the Needle Exchange Utilization Survey (NEXUS) to the Office of Management and Budget (OMB) for approval under the Paperwork Reduction Act. This survey aims to gather data on drug use, prevention behaviors, and infectious disease consequences in areas affected by the opioid crisis, focusing on urban and non-urban regions. The public has an additional 30 days to comment on the proposal. The CDC plans to use the data to improve prevention efforts and policymaking, especially in response to rising HIV and Hepatitis C cases linked to drug use.

The National Institute of Allergy and Infectious Diseases has announced a closed meeting scheduled from January 17 to 24, 2025, to review contract proposals relating to new drug classes for HIV, Hepatitis B, and Tuberculosis. The meeting will be conducted via video at the National Institutes of Health in Rockville, MD. This meeting is closed to the public due to confidentiality concerns, as it may involve sensitive information such as trade secrets and personal data. For more details, interested parties can contact Dr. Barry J. Margulies at the provided email address.